Einsatz oraler Antidiabetika in der Therapie des Kinderwunsches, des Gestationsdiabetes und zur Prävention des Typ-2-Diabetes

K. J. Bühling; J. Bartley; H. Lübbert

doi:10.1055/s-2006-923772

Geburtshilfe und Frauenheilkunde, Table of Contents

Geburtshilfe Frauenheilkd 2006; 66(3): 258-262
DOI: 10.1055/s-2006-923772

Übersicht

Georg Thieme Verlag KG Stuttgart · New York

Einsatz oraler Antidiabetika in der Therapie des Kinderwunsches, des Gestationsdiabetes und zur Prävention des Typ-2-Diabetes

Clinical Indications for Oral Antidiabetics in Infertility Treatments, Gestational Diabetes and Prevention of Type-2 Diabetes MellitusK. J. Bühling¹ ^, ² ^, ³ , J. Bartley³ , H. Lübbert³

¹Gemeinschaftspraxis BKS, Hamburg
²Klinik für Geburtsmedizin (Direktor: Prof. Dr. J. W. Dudenhausen), Charité - Universitätsmedizin Berlin
³Klinik für Frauenheilkunde und Geburtshilfe (Direktor: Prof. Dr. A. Schneider), Abt. für Gynäkologische Endokrinologie und Reproduktionsmedizin (Leiter: Prof. Dr. H. Lübbert), Charité - Universitätsmedizin Berlin, Campus Benjamin-Franklin, Berlin

Abstract

Zusammenfassung

Die Therapie des polyzystischen Ovarsyndroms (PCOS) hat in der vergangenen Zeit neue Impulse durch den Einsatz oraler Antidiabetika (OAD) erhalten. Der Übersichtsbeitrag gibt einen Einblick in die aktuelle Studienlage hinsichtlich des Einsatzes verschiedener OAD bei Kinderwunsch. Weiterer Schwerpunkt dieses Beitrages ist der Einsatz von OAD während der Schwangerschaft sowie post partum. Dabei wird auch auf den klinischen Wert einer Hyperinsulinämie eingegangen.

Abstract

The therapy of polycystic ovarian syndrome has changed considerably in recent years due to the use of oral antidiabetics (OAD). This review gives an overview of the present indications for different OAD in fertility treatment. The use during pregnancy and post partum and the significance of hyperinsulinaemia in this context is evaluated critically.

Schlüsselwörter

Orale Antidiabetika - Schwangerschaft - Gestationsdiabetes - Typ-2-Diabetes-mellitus - Hyperinsulinämie

Key words

Oral antidiabetics - pregnancy - gestational diabetes - type-2 diabetes - hyperinsulinaemia

Full Text

References

Literatur

1 Knick B, Schwarz P, Schernthaner G. et al .Metformin. Mehnert H et al. Metformin in der Diabetestherapie. Bremen; Uni-Med 2004
2 Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman M F, Goodyear L J, Moller D E. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001; 108 1167-1174
3 Legro R S, Kunselman A R, Dodson W C, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999; 84 165-169
4 Lord J M, Flight I H, Norman R J. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003; 327 951-953
5 Lord J M, Flight I H, Norman R J. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev. 2003; 3 CD003053
6 Nestler J E, Jakubowicz D J, Evans W S, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med. 1998; 338 1876-1880
7 Fleming R, Hopkinson Z E, Wallace A M, Greer I A, Sattar N. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab. . 2002; 87 569-574
8 George S S, George K, Irwin C, Job V, Selvakumar R, Jeyaseelan V, Seshadri M S. Sequential treatment of metformin and clomiphene citrate in clomiphene-resistant women with polycystic ovary syndrome: a randomized controlled trial. Hum Reprod. 2003; 18 299-304
9 Kjotrod S B, von During V, Carlsen S M. Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Hum Reprod. 2004; 19 1315-1322
10 Glueck C J, Phillips H, Cameron D, Sieve-Smith L, Wang P. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril. 2001; 75 46-52
11 Jakubowicz S, Roberts K A, Nestler J E, Jakubowicz D J, Iuorno M J. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab. 2002; 87 524-529
12 McCarthy E A, Walker S P, McLachlan K, Boyle J, Permezel M. Metformin in obstetric and gynecologic practice: a review. Obstet Gynecol Surv. 2004; 59 118-127
13 Glueck C J, Wang P, Kobayashi S, Phillips H, Sieve-Smith L. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril. 2002; 77 520-525
14 Langer O, Conway D L, Berkus M D, Xenakis E M, Gonzales O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med. 2000; 343 1134-1138
15 Jacobson G F, Ramos G A, Ching J Y, Kirby R S, Ferrara A, Field D R. Comparison of glyburide and insulin for the management of gestational diabetes in a large managed care organization. Am J Obstet Gynecol. 2005; 193 118-124
16 Azziz R, Ehrmann D, Legro R S, Whitcomb R W, Hanley R, Fereshetian A G, O'Keefe M, Ghazziy M N. PCOS/Troglitazone Study Group . Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2001; 86 1626-1632
17 Buchanan T A, Xiang A H, Peters R K, Kjos S L, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis H N, Azen S P. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes. 2002; 51 2796-2803
18 UK Prospective Diabetes Study (UKPDS) Group . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352 854-865
19 UK Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1999; 352 837-853 Lancet. 1999; 354 602
20 Diabetes Prevention Program Research Group . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346 393-403
21 Ruige J B, Assendelft W J, Dekker J M, Kostense P J, Heine R J, Bouter L M. Insulin and risk of cardiovascular disease: a meta-analysis. Circulation. 1998; 97 996-1001
22 Pyorala M, Miettinen H, Laakso M, Pyorala K. Hyperinsulinemia and the risk of stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Stroke. 1998; 29 1860-1866
23 Hu G, Qiao Q, Tuomilehto J, Eliasson M, Feskens E J, Pyorala K. DECODE Insulin Study Group . Plasma insulin and cardiovascular mortality in non-diabetic European men and women: a meta-analysis of data from eleven prospective studies. Diabetologia. 2004; 47 1245-1256
24 Tuomilehto J, Lindstrom J, Eriksson J G, Valle T T, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M. Finnish Diabetes Prevention Study Group . Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001; 344 1343-1350
25 Berger M, Mühlhauser I. Surrogat-Marker: Trugschlüsse. Dt Ärztebl. 1996; 49 A-3280

Priv.-Doz. Dr. med. DDG Kai J. Bühling Frauenarzt, Diabetologe

Gemeinschaftspraxis BKS

Schomburgstraße 120

22767 Hamburg

Email: kjbuehling@aol.com